A landmark trial in China has reported that a stem cell therapy reversed heart failure in 90% of patients, a result that could reshape how the world treats one of the deadliest cardiac conditions. The study, led by researchers at a major Chinese hospital, involved patients with severe heart failure who had not responded to standard treatments. After receiving the experimental therapy, most showed significant improvement in heart function, with some recovering enough to resume normal daily activities.
A new approach to repairing damaged hearts
The therapy uses stem cells derived from a patient's own body, which are then injected directly into the damaged heart muscle. Unlike conventional treatments that only manage symptoms, this approach aims to regenerate the heart tissue itself. In the trial, 90% of the 30 participants experienced measurable improvement in their heart's pumping ability within six months. The findings were published in a peer-reviewed journal and have drawn attention from cardiologists worldwide.
Why this matters for millions of patients
Heart failure affects over 64 million people globally, and in China alone, an estimated 13 million live with the condition. For many, the only long-term option is a heart transplant, which is scarce and risky. The trial's success suggests that a less invasive, regenerative therapy could become a viable alternative. Patients in the study reported fewer symptoms like breathlessness and fatigue, and some were able to reduce their reliance on other heart medications.
The trial was conducted at the Second Affiliated Hospital of Zhejiang University School of Medicine in Hangzhou, a city in eastern China. The research team, led by cardiologist Wang Jian'an, followed patients for a year after treatment. No serious side effects were reported, and the improvements appeared to be sustained over the follow-up period. Local residents in Hangzhou, where heart disease is a leading cause of death, have followed the news closely, with many hoping the therapy will soon become widely available.
The results are promising, but larger trials are needed to confirm the therapy's safety and effectiveness across a broader population. The Chinese team is already planning a phase III trial with more participants, and if successful, the treatment could be submitted for regulatory approval in China and other countries. For now, the study offers a rare piece of good news in the fight against heart failure, a condition that has long been considered irreversible.
